Cencora, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cencora, Inc. on January 12, 2026. The filing details the entry into material definitive agreements to secure financing for the proposed acquisition of the majority of outstanding equity interests in OneOncology that the Company does not currently own.
Key Financial Metrics and Debt Structure
The filing outlines significant changes to the Company's debt capacity and liquidity structure:
- Revolving Credit Facility: Increased by $1.0 billion to a total commitment of $5.5 billion.
- Multi-Year Term Loan Facility: Established a $1.5 billion senior unsecured term loan facility consisting of two tranches:
- Tranche One: $500 million (matures 2 years after draw).
- Tranche Two: $1.0 billion (matures 3 years after draw).
- 364-Day Term Loan Facility: Established a $3.0 billion senior unsecured term loan facility maturing 364 days after draw.
- Bridge Financing: Previously disclosed $4.5 billion in bridge financing commitments have been reduced to zero upon the execution of the new term facilities.
- Interest Rates:
- Multi-Year Term Loan margins range from 75 to 125 basis points over Term SOFR/Daily Simple SOFR.
- 364-Day Term Loan margins range from 87.5 to 112.5 basis points over Term SOFR/Daily Simple SOFR.
- Leverage Covenant: Financial leverage ratio not to exceed 4.00 to 1.00 (increasable to 4.50 to 1.00 during material acquisition quarters).
The filing does not provide specific values for revenue, profit, cash flow, or operating margins as this is a transactional report rather than a periodic financial statement.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's debt facilities to fund the OneOncology acquisition. The Company has replaced $4.5 billion in bridge financing with permanent term debt ($4.5 billion total in new term facilities) and expanded its revolving credit line by $1.0 billion.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: Proceeds from the new term loans will be used to pay a portion of the acquisition consideration, repay existing OneOncology debt, and cover associated fees and expenses. Funding is subject to customary conditions, including the consummation of the acquisition.
Risks and Contingencies:
- Acquisition Risk: The funding of the new term loans is contingent upon the successful closing of the OneOncology acquisition.
- Covenant Compliance: The Company must maintain a financial leverage ratio of 4.00 to 1.00 (or 4.50 to 1.00 under specific conditions). Failure to comply could trigger events of default.
- Interest Rate Exposure: Interest rates are variable, based on Term SOFR or Daily Simple SOFR plus applicable margins tied to credit ratings.
Key Facts for Investor Verification
- Verify the final closing status of the OneOncology acquisition, as the new debt funding is conditional upon this event.
- Monitor the Company's credit ratings from S&P, Moody's, and Fitch, as these directly impact interest rate margins and ticking fees.
- Review the Company's quarterly financial leverage ratio to ensure compliance with the 4.00 to 1.00 covenant threshold.
- Confirm the repayment schedule for the $3.0 billion 364-Day Term Loan, which matures in approximately one year.
- Assess the impact of the increased debt load on the Company's overall liquidity and interest coverage ratios.